1. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic
- Author
-
Roger G. Owen, Dipti Talaulikar, Ranjana H. Advani, Marzia Varettoni, Judith Trotman, Meletios A. Dimopoulos, Shirley D'Sa, Josephine M.I. Vos, Maria Jose Kersten, Jorge J. Castillo, Maria Lia Palomba, Steven P. Treon, Veronique Leblond, Monique C. Minnema, Andrew R. Branagan, Christian Buske, Efstathios Kastritis, and Alessandra Tedeschi
- Subjects
medicine.medical_specialty ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Statement (logic) ,lcsh:RC633-647.5 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,Waldenstrom macroglobulinemia ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,medicine.disease ,Clinical trial ,Guideline Article - Expert opinion ,Pandemic ,Medicine ,business ,Intensive care medicine - Abstract
In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel felt the need to provide a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. We followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. In this Consensus Statement, the Panel addresses questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. Finally, we also provide information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.
- Published
- 2020